Abstract: The present invention relates to the use of a film coating consisting of a) polyvinyl acetate b) hydrophilic additives c) other conventional coating ingredients d) and, where appropriate, a physiologically tolerated acid as taste-masking coating for oral dosage forms, and to a process for producing such dosage forms.

Abstract: A solid oral pharmaceutical dosage form of a sympathomimetic with impeded extractability of the sympathomimetic, comprising I) a sympathomimetic (component I) II) an excipient mixture (component II) composed of a) 5 to 50% by weight of hydroxyalkylcelluloses or alkylcelluloses or mixtures thereof b) 5 to 70% by weight of xanthan c) 5 to 50% by weight of an alkaline earth metal salt of a C10-C30 fatty acid d) 10 to 70% by weight of an alkali metal or alkaline earth metal salt of a mineral acid, of a sulfonic acid or of a C2-C6 carboxylic acid or mixtures thereof, where the total of components a) to d) is 100% by weight, where the ratio of active ingredient to excipient mixture II) is from 1:2 to 3:1 by weight.

Abstract: The present invention relates to a process for the formation of profen crystals, which comprises carrying out the formation of solids by displacement precipitation, cooling crystallization, evaporative crystallization or a combination thereof in the presence of one or more additives, and the use of the profens thus prepared for pharmaceutical formulations.

Abstract: A pharmaceutical mixture comprising a profen is described which has a profen content of over 85% and contains up to 1% of a nonionic surfactant having an HLB of ≧9 and also a customary disintegrant and a lubricant and optionally a microcrystalline cellulose.

Abstract: Medicaments in the form of soft gelatin capsules contain paroxetin anhydrate or pharmaceutically acceptable salts thereof together with lipophilic carriers, namely silicone oils.

Abstract: The present invention relates to an active ingredient preparation comprising ibuprofen, to a process for its production, to its use for producing pharmaceutical preparations and solid dosage forms, and to pharmaceutical preparations and solid dosage forms comprising the ibuprofen active ingredient preparation.

Abstract: Drugs comprising modification D of doxazosin mesylate are described. They are suitable for treating high blood pressure.

Abstract: Medicaments in the form of soft gelatin capsules contain paroxetin anhydrate or pharmaceutically acceptable salts thereof together with lipophilic carriers, namely silicone oils.

Abstract: The present invention relates to the use of a film coating consisting of

Abstract: A pharmaceutical mixture comprising a profen and one or more additional active compounds is described which has a total active compound content of over 85% and contains up to 1%, based on the content of the profen, of a nonionic surfactant having an HLB of ≧9 and a customary disintegrant and a lubricant.

Abstract: Solid oral administration forms from which the active ingredients can be isolated only with difficulty are described and comprise, besides conventional ingredients, as addition a mixture of pharmacologically suitable fats or gel formers with surfactants. Addition of the mixtures impedes extraction of the active ingredients out of the administration forms.

Abstract: An administration form for the release of collagenase to wounds is characterised in that it exhibits a combination of specific properties as hereinbelow:a. it is coherent, flat-shaped and deformable;b. it has a superficial extension that is equal to or smaller than the wound surface to be treated;c. it comprises collagenase in defined amounts in homogeneously distributed form;d. it is designed for the controlled release of collagenase.

Abstract: A mixture of an alginate and a polyacrylate in a ratio of from 15:1 to 1:2 is suitable for the preparation of depot drug forms.

Abstract: An alginate-based depot drug form for which the rate of release of the active substance in vitro can be adjusted very precisely is described.